According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the comparator assay in the primary study lacked sufficient sensitivity to support Talis’ Emergency Use Authorization (“EUA”) application for Talis One COVID-19 test;
- as a result, Talis was reasonably likely to experience delays in obtaining regulatory approval for the Talis One COVID-19 test;
- as a result, the Company’s commercialization timeline would be significantly delayed; and
- as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.